Julie Cooke - Jul 1, 2024 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Human Resources Officer
Signature
/s/ Darin Lippoldt, Attorney-In-Fact
Stock symbol
NBIX
Transactions as of
Jul 1, 2024
Transactions value $
-$783,664
Form type
4
Date filed
7/2/2024, 09:36 PM
Previous filing
Feb 15, 2024
Next filing
Jul 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $618K +10K +54.94% $61.82* 28.2K Jul 1, 2024 Direct F1
transaction NBIX Common Stock Sale -$1.4M -10K -35.46% $140.19 18.2K Jul 1, 2024 Direct F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Non-Qualified Stock Option Options Exercise $0 -10K -42.5% $0.00 13.5K Jul 1, 2024 Common Stock 10K $61.82 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes an aggregate of 226 shares purchased on February 29, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
F2 The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024.
F3 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.48. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 16,538 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.
F5 Represents option of which 1/4th of the shares underlying the option became vested and exercisable on October 2, 2018 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter. These options will expire ten years from the date of grant on October 2, 2027.